Cancer genes disfavoring T cell immunity identified via integrated systems approach

Area of Science:

• Immunology
• Cancer Biology
• Genetics

Background:

• Adoptive T-cell therapies (ACT) show promise but benefit a limited patient group.
• Sensitizing cancer cells to T-cell killing could broaden ACT applications.
• Identifying genes that shield tumors from T-cell immunity is crucial for therapeutic advancement.

Purpose of the Study:

• To identify cancer genes that suppress T-cell immunity.
• To discover novel targets for combination therapies with ACT.
• To validate potential drug targets for enhancing ACT efficacy.

Main Methods:

• Profiling gene transcripts upregulated under T-cell killing pressure.
• Utilizing CRISPR-Cas9 screens and pathway activation libraries to identify tumor gene targets.
• Conducting pharmacological perturbation screens to validate targets and drug combinations.

Main Results:

• Identified BIRC2, ITGAV, DNPEP, BCL2, and ERRα as potential ACT-drug combination candidates.
• Established that BIRC2 suppresses IRF1 activity, limiting antigen presentation and T-cell recognition.
• Demonstrated that BIRC2 inhibition enhances ACT efficacy.

Conclusions:

• BIRC2 is a key regulator of tumor immune evasion by inhibiting antigen presentation.
• Targeting BIRC2 in combination with ACT represents a promising strategy to improve cancer treatment outcomes.
• This research provides a foundation for developing novel combination therapies to expand ACT benefits.